Clinical Trial Update: A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma [Phase 3]

View source ↗

Summary

Reports the completion of a Phase 3 trial evaluating tadalafil for systemic sclerosis-associated interstitial lung disease (scleroderma).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• TADALAFIL (TADALAFIL)

Snippet

Sponsor: Sanjay Gandhi Postgraduate Institute of Medical Sciences | Conditions: Lung Diseases, Interstitial | Phase 3 | Status: COMPLETED